SCHEMBL26768331

SCHEMBL26768331

CCCCOc1ccc2c(c1)oc(=O)c1cc(O)ccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.61
MAPT P10636 4/20 0.61
XDH P47989 2/20 0.57
MAP1LC3B Q9GZQ8 1/20 0.56
MAP1LC3A Q9H492 1/20 0.56
ALDH1A1 P00352 5/20 0.54
RAB9A P51151 4/20 0.54
KDM4E B2RXH2 4/20 0.54
NPC1 O15118 3/20 0.54
POLB P06746 1/20 0.54
STAT1 P42224 1/20 0.54
MEN1 O00255 1/20 0.52
GAA P10253 1/20 0.52
KMT2A Q03164 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MAOB P27338 1/20 0.52
HPGD P15428 3/20 0.52
TSHR P16473 2/20 0.52
HSD17B10 Q99714 2/20 0.52
MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805441 0.95 MAPT (0.69) PDE2AMAPTXDHMAP1LC3BMAP1LC3A
SCHEMBL7758792 0.86 KDM4E (0.60) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL29894593 0.85 KDM4E (0.76) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL28627763 0.85 KDM4E (0.76) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL26766591 0.85 MAPT (0.63) PDE2AMAPTXDHMAP1LC3BMAP1LC3A
SCHEMBL29894611 0.85 ACHE (0.67) MAPTALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL28629168 0.85 ACHE (0.67) MAPTALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL26768333 0.84 KDM4E (0.54) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL8868179 0.84 XDH (0.77) MAPTXDHMAP1LC3BMAP1LC3AALDH1A1
SCHEMBL28922154 0.83 KDM4E (0.52) MAPTALDH1A1RAB9AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820751-B2 Urolithin derivatives and methods of use thereof VANDRIA SA (CH) 2023-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820751-B2 Urolithin derivatives and methods of use thereof NLN, UQCRC2, TUFM PDE2A 1089/4885MAPT 217/4885XDH 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.